GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Radiopharm Theranostics
Radiopharm is a biotech company specializing in radiopharmaceuticals for cancer diagnostics and treatment. Its stock price is a bet on the growth of this promising area. The chart reflects news from clinical trials and partnerships.
Share prices of companies in the market segment - Cancer cure
Radiopharm Theranostics is an Australian biotechnology company developing radiopharmaceuticals (combinations of a radioisotope and a targeting molecule) for the diagnosis and treatment of cancer. We have classified it in the "Cancer Cure" segment. The chart below shows the overall dynamics of this innovative nuclear medicine sector.
Broad Market Index - GURU.Markets
Radiopharm Theranostics is an Australian biotech company developing radiopharmaceuticals for cancer diagnostics and treatment. It is a component of the GURU.Markets index. The chart below shows the US market. See how this company's stock compares to the US market trend.
Change in the price of a company, segment, and market as a whole per day
RADX - Daily change in the company's share price Radiopharm Theranostics
For Radiopharm Theranostics, which develops radiopharmaceuticals for cancer treatment, daily volatility reflects sensitivity to clinical trial data. This metric is an important element in assessing risks in this innovative field.
Daily change in the price of a set of shares in a market segment - Cancer cure
Radiopharm Theranostics Limited is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with RADX's dynamics, which depend on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Radiopharm Theranostics is an Australian biotech company developing radiopharmaceuticals for the diagnosis and treatment of cancer. Its shares bring the dynamism of this cutting-edge medical field to the US market, adding an international dimension to the overall volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Radiopharm Theranostics
Radiopharm Theranostics' year-to-date performance is a story about the development of targeted radiopharmaceuticals. Its 12-month market cap depends entirely on progress in its extensive clinical pipeline. Success with any of its candidates, which deliver radiation directly to tumors, could be a breakthrough in nuclear medicine.
Annual dynamics of market capitalization of the market segment - Cancer cure
Radiopharm, a company developing radiopharmaceuticals, is betting on a new cancer treatment. Its performance relative to the sector will demonstrate the extent to which investors believe in its ability to successfully conduct clinical trials and commercialize this complex but promising technology.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Radiopharm is a clinical-stage biotech company whose fate depends on scientific breakthroughs, not the state of the economy. Its share price (ADR) reflects investor hopes for the success of its radiopharmaceutical trials. The company's chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Radiopharm Theranostics
Radiopharm Theranostics is a company developing radiopharmaceuticals for the diagnosis and treatment of cancer. Its monthly growth is entirely dependent on progress in its clinical pipeline. News about the results of trials of its various drug candidates are the main drivers.
Monthly dynamics of market capitalization of the market segment - Cancer cure
Radiopharmaceuticals is a niche in oncology that uses radioactive isotopes to diagnose and treat cancer. The dynamics of this sector, shown in the chart, reflect investor interest in this cutting-edge approach. Companies like Radiopharm Theranostics are pursuing research in this area.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Radiopharm Theranostics, a company developing radiopharmaceuticals for cancer diagnostics and treatment, is a high-risk biotech. Its shares are driven solely by news of clinical trials, completely ignoring the market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Radiopharm Theranostics
Short-term price fluctuations for Radiopharm Theranostics, a company developing radiopharmaceuticals for cancer diagnostics and treatment, are extremely high. News about clinical trials and partnerships with major pharmaceutical companies are driving sharp speculative movements.
Weekly dynamics of market capitalization of the market segment - Cancer cure
Radiopharm Theranostics and the entire nuclear medicine sector are moving forward against a backdrop of scientific breakthroughs and investment. Demand for new cancer diagnostic and treatment methods is driving everyone. The chart will show how the company fares in this innovative, yet risky, field.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Radiopharm Theranostics and the entire nuclear medicine sector are moving forward against a backdrop of scientific breakthroughs and investment. Demand for new cancer diagnostic and treatment methods is driving everyone. The chart will show how the company fares in this innovative, yet risky, field.
Market capitalization of the company, segment and market as a whole
RADX - Market capitalization of the company Radiopharm Theranostics
Radiopharm Theranostics' market capitalization is the financial valuation of a company working in the field of theranostics—a combination of diagnostics and therapy using radioactive isotopes. The chart reflects expectations for its cancer treatment pipeline. Its speculative dynamics tell the story of how the market values this cutting-edge yet complex field of medicine.
RADX - Share of the company's market capitalization Radiopharm Theranostics within the market segment - Cancer cure
Radiopharm Theranostics is a company developing radiopharmaceuticals for the diagnosis and treatment of cancer. Its market share reflects its position at the forefront of "theranostics"—the "see and treat" approach. The chart below shows the market's weighting for this new generation of nuclear medicine.
Market capitalization of the market segment - Cancer cure
Radiopharm Theranostics develops radiopharmaceuticals for cancer diagnostics and treatment. The chart below shows the overall market capitalization of this entire sector. It reflects the renewed interest in "smart bombs" that deliver radiation directly to tumor cells, which is Radiopharm's goal.
Market capitalization of all companies included in a broad market index - GURU.Markets
The radiopharmaceuticals shown in the chart use radiation to diagnose and treat cancer. Radiopharm Theranostics develops drugs that deliver radioactive isotopes directly to tumors. Its capitalization represents a risky bet on this complex but promising class of drugs.
Book value capitalization of the company, segment and market as a whole
RADX - Book value capitalization of the company Radiopharm Theranostics
Radiopharm's book value represents a portfolio of radiopharmaceuticals. The chart reflects investments in clinical trials of various candidates that use radioactive isotopes for cancer diagnosis and treatment. These financial assets are aimed at developing a new class of oncology drugs.
RADX - Share of the company's book capitalization Radiopharm Theranostics within the market segment - Cancer cure
Radiopharm Theranostics, a nuclear medicine company, has a lightweight asset structure. Its share of the sector is minimal. Its business model is based on the development and licensing of radiopharmaceuticals, rather than on owning its own cyclotrons or manufacturing facilities.
Market segment balance sheet capitalization - Cancer cure
Radiopharm Theranostics is a radiopharmaceutical company, making it moderately capital-intensive. It doesn't require large factories, but it does require specialized laboratories and production facilities to handle radioactive isotopes. Compared to the biotech sector, its model requires unique physical assets.
Book value of all companies included in the broad market index - GURU.Markets
Radiopharm's assets are not traditional drugs, but a portfolio of radiopharmaceuticals that simultaneously diagnose and treat cancer using "smart" radioactive molecules. The company's balance sheet reflects the value of these developments. The chart shows how much capital is invested in this promising area—theranostics.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Radiopharm Theranostics
Radiopharm Theranostics is a company developing radiopharmaceuticals for the diagnosis and treatment of cancer. Its market capitalization is a valuation of its development pipeline. Investors are betting that this "see-and-treat" approach will become a key part of oncology.
Market to book capitalization ratio in a market segment - Cancer cure
Radiopharm Theranostics develops radiopharmaceuticals for the diagnosis and treatment of cancer, one of the hottest areas in oncology. This chart shows how the market views the potential of this cutting-edge technology, offering a high premium to the company's current assets.
Market to book capitalization ratio for the market as a whole
Radiopharm Theranostics develops radiopharmaceuticals for the diagnosis and treatment of cancer. The company's market capitalization is based on the potential of this cutting-edge technology. The chart shows the significant premium investors are paying for research in one of the most promising areas of oncology, compared to the market average.
Debts of the company, segment and market as a whole
RADX - Company debts Radiopharm Theranostics
Radiopharm Theranostics develops radiopharmaceuticals for the diagnosis and treatment of cancer. This field requires access to specialized manufacturing facilities and significant clinical trial expenditures. Debt financing helps the company advance its portfolio of targeted radioactive drugs.
Market segment debts - Cancer cure
Radiopharm Theranostics develops radiopharmaceuticals for the diagnosis and treatment of cancer. This is a capital-intensive and high-tech field. This chart shows how the company finances its diversified pipeline of candidates at various stages of development, which is key to risk allocation in biotechnology.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Radiopharm Theranostics
Radiopharm Theranostics develops radiopharmaceuticals for cancer diagnostics and treatment. This chart shows its reliance on debt capital. This is one of the most capital-intensive areas of biotech. The high debt here means the company is placing a huge bet on the success of its complex and expensive-to-produce drugs.
Market segment debt to market segment book capitalization - Cancer cure
Radiopharm Theranostics develops radiopharmaceuticals for the diagnosis and treatment of cancer. This approach, known as theranostics, allows for the simultaneous detection and treatment of tumors. This chart compares the debt raised for this cutting-edge research to the overall market capitalization of the entire sector, highlighting the financial implications of this promising field of oncology.
Debt to book value of all companies in the market
Radiopharm Theranostics develops radiopharmaceuticals for the diagnosis and treatment of cancer. This is a cutting-edge, yet capital-intensive, field. The chart demonstrates how the company finances its long-term research. Comparing its debt load with the biotech sector allows one to assess the financial risks and dependence on external capital on the path to success.
P/E of the company, segment and market as a whole
P/E - Radiopharm Theranostics
This chart for Radiopharm Theranostics, a company developing radioactive drugs for cancer diagnostics and treatment, is an assessment of the future of nuclear medicine. Investors estimate its potential profits to be very high due to the promising nature of this approach. The stock's performance is a reaction to clinical trial data from its various "smart bombs" against cancer.
P/E of the market segment - Cancer cure
This chart reflects the average valuation for the speculative biotech sector—a benchmark for Radiopharm. For investors, it serves as a benchmark, indicating the overall level of optimism in the radiopharmaceuticals field. Against this backdrop, one can gauge expectations for the company's diversified development portfolio.
P/E of the market as a whole
Radiopharm Theranostics develops radiopharmaceuticals that can simultaneously diagnose and treat cancer. This field, known as "theranostics," is one of the most promising in oncology. This chart shows the market's risk appetite, providing insight into how investors view the company's development pipeline and its chances of success in this cutting-edge field of medicine.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Radiopharm Theranostics
Radiopharm Theranostics develops radiopharmaceuticals for both diagnostics and cancer treatment (theranostics). Future revenue depends on the success of its clinical programs. This chart reflects analyst expectations for the growth of this cutting-edge oncology practice and the potential of the company's development pipeline.
%20P%2FE%20Radiopharm%20Theranostics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Radiopharm-Theranostics&v=1772673914027 "Chart of the company's future (projected) P/E Radiopharm Theranostics")
Future (projected) P/E of the market segment - Cancer cure
Radiopharm Theranostics develops radiopharmaceuticals for both cancer diagnostics and treatment. This chart compares its future profitability expectations with the biotech sector. It demonstrates how the market views its theranostics approach, which allows for tumor imaging and then targeting it with radioactive isotopes.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772673914032 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
Radiopharm Theranostics develops radiopharmaceuticals for the diagnosis and treatment of cancer. This chart shows the company's overall risk appetite. Radiopharm's success depends on progress in its clinical programs. A positive market environment is important for raising capital, but it cannot replace successful scientific results.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772673914215 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Radiopharm Theranostics
Radiopharm Theranostics is a clinical-stage company developing radiopharmaceuticals for both diagnostics and cancer treatment (theranostics). This chart shows the company's financial trajectory, based on cutting-edge nuclear technologies. The results reflect investments in the development of next-generation targeted radiation therapy.
Profit of companies in the market segment - Cancer cure
Radiopharm Theranostics is a company developing radiopharmaceuticals for both cancer diagnostics and therapy. This approach, called "theranostics," allows for tumor detection and then targeted destruction. This graph illustrates the financial climate in the oncology sector, reflecting the potential of personalized and highly precise treatments.
Overall market profit
Radiopharm Theranostics develops radiopharmaceuticals for the diagnosis and treatment of cancer. This is a cutting-edge field of medicine, the success of which depends on scientific breakthroughs and trial results. The company's business is not affected by economic cycles, but it requires significant investment, which is easier to attract in a growing market.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Radiopharm Theranostics
Radiopharm Theranostics develops radiopharmaceuticals—smart molecules that deliver radiation directly to cancer cells for diagnosis and treatment. This schedule represents a long-term model based on analysts' belief in the potential of this cutting-edge field in oncology.
%20profit%20of%20the%20company%20Radiopharm%20Theranostics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Radiopharm-Theranostics&v=1772673914319 "Graph of future (projected) profit of the company Radiopharm Theranostics")
Future (predicted) profit of companies in the market segment - Cancer cure
Radiopharm Theranostics develops radiopharmaceuticals for both cancer diagnostics and therapy. This chart shows forecasts for the innovative nuclear medicine sector. The company's profitability depends on the success of its "theranostic" approach, which first visualizes tumors and then specifically destroys them with radiation.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772673914359 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
Radiopharm Theranostics specializes in developing radiopharmaceuticals for cancer diagnostics and treatment. This cutting-edge field requires significant investment. This graph, reflecting profit expectations, illustrates the overall investment climate and risk appetite, which are key factors in attracting capital to such innovative biotech companies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772673914416 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Radiopharm Theranostics
Radiopharm Theranostics develops radiopharmaceuticals for the diagnosis and treatment of cancer. This chart shows that the company's valuation is based on future potential. It reflects investors' hopes that its "see and treat" approach will become the new standard in personalized oncology.
P/S market segment - Cancer cure
Radiopharm Theranostics is an Australian company developing radiopharmaceuticals (a combination of a radioisotope and a targeted molecule) for the diagnosis and treatment of cancer. This chart reflects the average biotech valuation, helping to understand how highly the market values this promising field of "theranostics," where diagnosis and treatment go hand in hand.
P/S of the market as a whole
Radiopharm Theranostics develops radiopharmaceuticals for both diagnostics and treatment of cancer. This is a promising area of "theranostics." This graph of average market revenue valuation contrasts sharply with the company's value, demonstrating that its valuation is based on the potential of this innovative technology in oncology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Radiopharm Theranostics
Radiopharm Theranostics develops radiopharmaceuticals for both cancer diagnostics and treatment. This chart reflects investor confidence in the future of this oncology field. The valuation is based on the potential revenue from its portfolio of drugs that can simultaneously detect and destroy cancer cells.
%20P%2FS%20Radiopharm%20Theranostics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Radiopharm-Theranostics&v=1772673914569 "The graph of the company's future (projected) P/S Radiopharm Theranostics")
Future (projected) P/S of the market segment - Cancer cure
Radiopharm Theranostics develops radiopharmaceuticals for the diagnosis and treatment of cancer. This chart compares the company's future revenue expectations with its sector. It reflects investor confidence in the potential of this "smart" approach, which allows for the simultaneous detection and treatment of tumors.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772673914643 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
Radiopharm Theranostics is a company developing radiopharmaceuticals for both diagnostics and cancer treatment (theranostics). This chart reflects confidence in future growth, as Radiopharm operates at the intersection of two disciplines. The success of its "see what I treat" approach could lead to the development of highly precise and personalized cancer treatments.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772673914742 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Radiopharm Theranostics
Radiopharm Theranostics is a clinical-stage company developing radiopharmaceuticals for the diagnosis and treatment of cancer. It currently has no commercial products, and revenue, if reflected in this chart, likely comes from licensing agreements or research grants.
Sales of companies in the market segment - Cancer cure
Radiopharm Theranostics is a company developing radiopharmaceuticals for the diagnosis and treatment of cancer. This approach, known as "theranostics," allows for the simultaneous detection and treatment of tumors. This graph reflects the progress in nuclear medicine, which is experiencing a renaissance thanks to innovative companies like these.
Overall market sales
Radiopharm Theranostics develops radiopharmaceuticals for the diagnosis and treatment of cancer. The company's operations require significant investment. The growth in total revenue, reflected in this chart, creates a favorable investment climate. This facilitates raising the capital needed to conduct expensive clinical trials and bring products to market.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Radiopharm Theranostics
Radiopharm Theranostics develops radiopharmaceuticals that can both diagnose and specifically treat cancer by delivering radiation directly to tumor cells. This graph reflects analysts' expectations for clinical trial progress in this promising field of "theranostics."
%20sales%20of%20the%20company%20Radiopharm%20Theranostics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Radiopharm-Theranostics&v=1772673914892 "Schedule of future (projected) sales of the company Radiopharm Theranostics")
Future (projected) sales of companies in the market segment - Cancer cure
Radiopharm Theranostics is a company developing radiopharmaceuticals for both cancer diagnostics and therapy. This approach, known as theranostics, enables the precise targeting and destruction of tumors. This graph shows forecasts for the cancer treatment sector, reflecting the potential of personalized nuclear medicine.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772673914916 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
Radiopharm Theranostics, a company developing drugs for cancer diagnostics and treatment, sees this chart as an indicator of investment activity in biotech. The strong economics reflected here facilitate the influx of capital needed to conduct clinical trials and bring a new class of radiopharmaceuticals to market.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772673914956 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Radiopharm Theranostics
Radiopharm Theranostics is a biotechnology company developing radiopharmaceuticals for both diagnostics and treatment of cancer. Being in the clinical stage, the company incurs significant research expenditures. This chart shows the investment required to advance this cutting-edge technology through clinical trials.
Market segment marginality - Cancer cure
Radiopharm Theranostics develops radiopharmaceuticals for the diagnosis and treatment of cancer. This approach, called "theranostics," requires high efficiency in managing both the diagnostic and therapeutic components. The chart shows how profitable this complex business model is compared to other oncology companies.
Market marginality as a whole
Radiopharm Theranostics develops radiopharmaceuticals for both diagnostics and cancer treatment (theranostics). This chart shows average profitability, and Radiopharm operates in one of the most advanced areas of oncology. Their success depends on their drug portfolio and the development of nuclear medicine.
Employees in the company, segment and market as a whole
Number of employees in the company Radiopharm Theranostics
Radiopharm Theranostics develops radiopharmaceuticals for the diagnosis and treatment of cancer. This graph shows its team of scientists and nuclear medicine specialists. The size of its staff is an indicator of the breadth of its clinical and preclinical pipeline in this promising area of oncology.
Share of the company's employees Radiopharm Theranostics within the market segment - Cancer cure
Radiopharm Theranostics develops radiopharmaceuticals for the diagnosis and treatment of oncological diseases. This approach requires unique expertise. The chart shows the percentage of all nuclear medicine and oncology specialists the company attracts. This is a measure of its scientific potential and focus on creating "smart" radioactive drugs.
Number of employees in the market segment - Cancer cure
Radiopharm Theranostics is a company developing radiopharmaceuticals for cancer diagnostics and treatment. Its staff consists of radiochemists, oncologists, and clinical research specialists. This chart shows R&D activity. Team growth is an indicator of progress in development and clinical trials.
Number of employees in the market as a whole
Radiopharm Theranostics develops radiopharmaceuticals for the diagnosis and treatment of cancer. This is a capital-intensive industry dependent on investment. This chart provides a general overview, but for Radiopharm, successful completion of the trial phases is more important, as it opens access to funding and allows for team expansion.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Radiopharm Theranostics (RADX)
Radiopharm Theranostics is a biotech company operating at the intersection of nuclear medicine and oncology. Its market capitalization is the market's valuation of its unique platform. A high value on this chart is typical for science-intensive companies, where intellectual property is their primary asset.
%20of%20the%20company%20Radiopharm%20Theranostics%20(RADX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Radiopharm-Theranostics-RADX&v=1772673915240 "Chart of market capitalization per employee (in thousands of dollars) of the company Radiopharm Theranostics (RADX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
Radiopharm Theranostics develops radiopharmaceuticals for the diagnosis and treatment of cancer. In this cutting-edge field of medicine, a company's value is determined by its development pipeline. This metric reflects how the market perceives the potential of these "smart" drugs per scientist working on their development.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772673915243 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
Radiopharm Theranostics develops radiopharmaceuticals for the diagnosis and treatment of cancer, a cutting-edge field in nuclear medicine. This chart illustrates how the market values the company, whose value is determined by its portfolio of isotopes and targeted molecules, which form the basis for the creation of a new class of precision oncology drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772673915248 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Radiopharm Theranostics (RADX)
Radiopharm Theranostics is an Australian biotech company developing radiopharmaceuticals (targeted radiation) for cancer diagnosis and treatment. It's an R&D company. This chart shows the R&D capital burn per scientist. This represents investment in one of the hottest areas of oncology.
%20Chart%20Radiopharm%20Theranostics%20(RADX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Radiopharm-Theranostics-RADX&v=1772673915263 "Company Profit Per Employee (in thousands of dollars) Chart Radiopharm Theranostics (RADX)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
Radiopharm Theranostics (RADX) is a company developing radiopharmaceuticals for both diagnostics and cancer treatment (theranostics). This is a complex and capital-intensive field. This chart shows how effectively the team (physicists, chemists, and physicians) utilizes capital to advance its portfolio of isotope drugs through clinical trials.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772673915271 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
Radiopharm Theranostics is a company developing radiopharmaceuticals for cancer diagnostics and treatment. This is one of the most promising areas in oncology. This chart shows that the company is in the R&D investment phase. Its profit per employee is negative, as its staff of highly qualified physicists, chemists, and physicians is developing products that have not yet reached the market.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772673915303 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Radiopharm Theranostics (RADX)
Radiopharm Theranostics develops radiopharmaceuticals for the diagnosis and treatment of cancer. During clinical development, this graph is an indicator of future potential. Any revenue per employee will likely come from partnerships rather than commercial sales, but it will signal progress.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Radiopharm-Theranostics-RADX&v=1772673915321 "Sales chart per company employee Radiopharm Theranostics (RADX)")
Sales per employee in the market segment - Cancer cure
Radiopharm Theranostics is a company developing radiopharmaceuticals (combinations of a radioisotope and a targeting molecule) for cancer diagnostics and treatment. This chart shows the average revenue per employee in the sector. It serves as a benchmark in the complex field of "theranostics," demonstrating the level of productivity required to commercialize nuclear medicine.
Sales per employee for the market as a whole
Radiopharm Theranostics (RADX) is an Australian biotechnology company developing radiopharmaceuticals for cancer diagnostics and treatment. It is an R&D company staffed by scientists. This graph shows the current (zero) commercial return per employee pending clinical trial results.
Short shares by company, segment and market as a whole
Shares shorted by company Radiopharm Theranostics (RADX)
Radiopharm Theranostics is an Australian company developing "theranostics"—drugs that simultaneously diagnose and treat cancer using radioactive isotopes. This involves complex logistics and science. The chart shows the number of investors betting that the company will fail to establish complex manufacturing or that its candidates will fail in clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Radiopharm-Theranostics-RADX&v=1772673915483 "Short Shares Chart for the Company Radiopharm Theranostics (RADX)")
Shares shorted by market segment - Cancer cure
Radiopharm Theranostics is a company betting on "theranostics"—the use of radioactive isotopes for both cancer diagnosis and treatment. This chart reflects skepticism about this entire niche. Its growth suggests investors are concerned about logistics or safety issues with radiopharmaceuticals, which poses a barrier to the entire industry.
Shares shorted by the overall market
Radiopharm Theranostics is betting on radiopharmaceuticals for cancer diagnostics and treatment. This is a complex and expensive technology. This chart measures overall market pessimism. When fear prevails, investors prefer to flee to cash or defensive assets, selling off pre-profit biotech stocks en masse, like RADX, regardless of their scientific potential.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Radiopharm Theranostics (RADX)
Radiopharm Theranostics is a company developing radiopharmaceuticals for cancer diagnostics and treatment. It's at the cutting edge of oncology. This chart shows how quickly investor sentiment can shift: positive research data can trigger a sharp "overheating" (above 70), while any delays can lead to panicky "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Radiopharm-Theranostics-RADX&v=1772673915601 "RSI 14 indicator chart for the company's stock Radiopharm Theranostics (RADX)")
RSI 14 Market Segment - Cancer cure
Radiopharm (RADX) — "radiation" against cancer (Australia). They *don't* treat, but *develop* (R&D) *radiopharmaceuticals* (diagnostics + therapy = "theranostics"). The "Cancer cure" sector (biotech/radiopharmaceuticals) thrives on hype. RSI\_14\_Seg shows the "temperature" of the *entire* industry. It helps understand: is RADX's growth a niche or a general hype?
RSI 14 for the overall market
Radiopharm Theranostics (RADX) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast RADX (Radiopharm Theranostics)
Radiopharm (RADX) is a biotech company developing radiopharmaceuticals—drugs that deliver radiation precisely to cancer cells. This chart shows the average target price. It reflects analysts' speculative valuations of this promising oncology sector and the company's development pipeline.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-RADX-Radiopharm-Theranostics&v=1772673915800 "A chart showing analyst consensus forecasts for the expected stock price. RADX (Radiopharm Theranostics)")
The difference between the consensus estimate and the actual stock price RADX (Radiopharm Theranostics)
Radiopharm Theranostics (RADX) is an Australian biotech company developing "radiopharmaceuticals"—smart molecules that deliver radiation precisely to cancer cells. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the high, yet speculative, potential analysts see in their pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-RADX-Radiopharm-Theranostics&v=1772673915888 "A chart showing the difference between the consensus forecast and the actual stock price. RADX (Radiopharm Theranostics)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
Radiopharm Theranostics is an Australian biotech company developing "theranostics"—drugs that simultaneously detect (diagnose) and destroy (treat) cancer using radioisotopes. This chart shows general expectations for the oncology sector. It reflects whether experts believe in "nuclear medicine" for cancer.
Analysts' consensus forecast for the overall market share price
Radiopharm is a clinical-stage biotech company specializing in "radiopharmaceuticals" (targeted radiation). It is a risky R&D venture. This chart, which measures the market's overall "risk appetite," is crucial. When optimism prevails, investors are willing to fund capital-intensive R&D. When pessimism rises, funding for companies like RADX becomes scarce.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Radiopharm Theranostics
Radiopharm Theranostics is a biotech company operating in the hot field of theranostics. They are developing radioactive drugs that can simultaneously (1) find (diagnose) and (2) destroy (treat) cancer cells. This chart is a clear indicator of faith in their R&D. Its dynamics are a speculative market assessment of their complex nuclear pipeline and their chances of success.
AKIMA Market Segment Index - Cancer cure
Radiopharm Theranostics (RADX) is an Australian biotech company developing radiopharmaceuticals (theranostics)—smart molecules that simultaneously diagnose and treat cancer. The chart shows the segment average, helping investors assess how the risks and potential of this cutting-edge oncology company compare to the average.
The AKIM Index for the overall market
Radiopharm Theranostics is an Australian company developing radiopharmaceuticals for cancer diagnostics and treatment. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative story in the hot nuclear medicine sector compares to overall economic trends.
